Bill Biggs Email & Phone Number

• Discovery and use of molecular & genomics-based diagnostic markers for acute & chronic disease management.
• Development and Execution of operational, business, financial, and technical plans in preparation for product and service launch efforts.
• Evaluation of potential novel embodiments of intellectual property.

Palo Alto, California, US

• Founding leader establishing on-premises Production and R&D operations for multiple NGS-based products at new location supporting over 100 team members.
• Identified, recruited, and managed licensed and unlicensed team members across various disciplines (Bioinformatics, Software Engineering, IT infrastructure & Laboratory) required for production technology operations
• Negotiated with key Business Unit leaders to converge on optimal path validation and deployment of regulated testing platform.
• Negotiated with technology and automation partners for optimal deployment and transparency.
• Worked closely with key stakeholders (R&D, HR, BD, Supply Chain Management, Finance, Facilities, Legal & Regulatory) to renovate, equip, qualify and validate new laboratory & offices

Seattle, WA, US

• Member of founding leadership team addressing global healthcare concern through cutting-edge technology..
• Identified, recruited, and managed Operations, R&D and Data Infrastructure (ML/AI, Bioinformatics, Software Engineering & IT infrastructure) teams.
• Lead efforts to equip and operationalize cutting edge Life Sciences Laboratories.
• Worked closely with key stakeholders (Finance, Facilities, Legal & Regulatory) to enable new operational area (Life Sciences) within the Amazon organization.

San Diego, CA, US

• Lead cross-functional team major upgrades (mechanical & software) upgrades to over 3,000 RUO (NextSeq) and FDA-cleared (NextSeqDx) NGS instruments across over 1,000 customer locations.
• Initiated communication channels & venues to improve customer representation.
• Managed multi-site & internal efforts with critical resources located in Asia, Europe and US.
• Negotiated with key Business Unit leaders to converge on optimal changes to the platform.
• Coordinated platform extension activities including design change, development, verification, and validation to deliver new applications and/or performance/robustness enhancements

San Diego, CA, US

• Assembled and lead cross-functional team that produced over 40,000 human and 6,000 microbiome genomes in 3 years.
• Participated in the generation and analysis of both Germline and Somatic datasets for assessment of role in oncology, cardiovascular, immunological and metabolic disorders.
• Recruited and managed team members in Operations, Technical Development, Quality & Materials Management areas.
• Lead integrated team in development of customized scalable NGS-based workflows including Specimen stabilization (human & microbiome), Sample extraction (DNA & RNA), WGS (PCR & PCR-Free), WES (Whole Exome and.
• Best in class operational performance with over 95% “first pass” acceptance (WGS mean coverage: 30x) in production testing and over 90% operational availability for key production line equipment
• Established and managed development & production "farm" that included 8 NovaSeq6000, 24 HiSeqX, 6 HiSeq4000, 2 PacBio RS II as well as multiple automated liquid handling platforms (e.g. Hamilton & Tecan)

Cambridge, MA, US

• Define strategic and tactical goals for clinical sequencing at the Broad.
• Developed and managed relationships between the Broad and clinical partners.
• Establish regular forums for communication between clinical investigators and Broad scientists.
• Report on progress, risks, and opportunities to the Board of Managers and/or Board of Directors.
• Drive the development of specific clinical sequencing products, specifically setting specifications for genomic target, sets of genes, coverage required, or data type (DNA or RNA sequence data).
• Monitor competitive landscape to define opportunities for new tests or markets.

• Directed all DNA & RNA – based research/development
• Lead effort to identify and secure key talent to establish Molecular Genetics Team
• Managed large discovery and validation screens for non – coding RNAs predictive of CVD risk
• Initiated & lead analytical validation of NGS – based Cardiovascular Disease Genetics program
• Initiated & lead NGS – based software development program
• Oversaw validation of equipment, testing, outcomes and results – reporting for twenty – three (23) production tests successfully transferred to clinical laboratory

• Directed all DNA & RNA – based research/development
• Lead effort to identify and secure key talent to establish Molecular Genetics Team
• Managed large discovery and validation screens for non – coding RNAs predictive of CVD risk
• Initiated & lead analytical validation of NGS – based Cardiovascular Disease Genetics program
• Initiated & lead NGS – based software development program
• Oversaw validation of equipment, testing, outcomes and results – reporting for twenty – three (23) production tests successfully transferred to clinical laboratory

• Directed all laboratory research/development and clinical trials operations
• Serve as expert technology reference to Clinical Laboratory
• Oversaw validation of equipment, testing, outcomes and results – reporting for all feasibility and validations transferred to clinical laboratory and clinical trials
• Provide technical input to Laboratory Manager and Laboratory Director
• Established pricing schedules for a variety of standard (eg. IHC) and esoteric (eg. Sequencing, qPCR, LCM) service offerings
• Participated in the development of client – facing sales collateral

Santa Clara, California, US

• Directed all laboratory research and clinical trials operations and staff
• Facility capacity 100,000 tests/arrays per year
• Initiated & managed day to day relationship with pioneering Direct – to – Consumer (DTC) genetics testing company
• Developed and managed secure data analysis and transfer processes
• Oversaw validation of equipment, testing, outcomes and results – reporting for all feasibility and validations transferred to clinical laboratory and clinical trials
• Train and supervise personnel associated with proprietary techniques and processes

• Developed assays to elucidate mechanisms underlying the negative regulation of FoxO – related transcription factors by the Phosphatidylinositol – 3 kinase (PI – 3 kinase) – activated signal transduction pathway.
• Generated & characterized lines of 'ʹknock – out'ʹ mice lacking Foxo1, Foxo3, & Mllt7 loci.
• Isolated & characterized orthologs of the human forkhead – related transcription factor, FoxO1, expressed during development in mouse, chick, & zebrafish.
• Identified potential in vivo transcriptional targets of FKHR1 via mRNA profiling.
• Established chromosomal location of mouse FoxO – related loci through Inter – Specific Backcross Maps
• Identification and mapping of heritable traits using genetic markers (VNTR, RLFP, and SNP).

• Developed project to identify & assess a requirement for orthologs of the MAP kinases ERK1 & 2 expressed during retinal development in Drosophila melanogaster.
• Determined that Drosophila MAP kinase is encoded by the rolled (rl) locus.
• Integrated Drosophila rolled/MAP kinase into the sevenless (sev) signal transduction pathway regulating the development of the R7 photoreceptor cell.

La Jolla, CA, US

Phd, Biological Chemistry

Bachelor Of Arts, Microbiology